An anonymous reader quotes a report from IEEE Spectrum: In a development straight out of science fiction, Australian startup Cortical Labs has released what it calls the world's first code-deployable biological computer. The CL1, which debuted in March, fuses human brain cells on a silicon chip to process information via sub-millisecond electrical feedback loops. Designed as a tool for neuroscience and biotech research, the CL1 offers a new way to study how brain cells process and react to stimuli. Unlike conventional silicon-based systems, the hybrid platform uses live human neurons capable of adapting, learning, and responding to external inputs in real time. "On one view, [the CL1] could be regarded as the first commercially available biomimetic computer, the ultimate in neuromorphic computing that uses real neurons," says theoretical neuroscientist Karl Friston of University College London. "However, the real gift of this technology is not to computer science. Rather, it's an enabling technology that allows scientists to perform experiments on a little synthetic brain."

The first 115 units will begin shipping this summer at $35,000 each, or $20,000 when purchased in 30-unit server racks. Cortical Labs also offers a cloud-based "wetware-as-a-service" at $300 weekly per unit, unlocking remote access to its in-house cell cultures. Each CL1 contains 800,000 lab-grown human neurons, reprogrammed from the skin or blood samples of real adult donors. The cells remain viable for up to six months, fed by a life-support system that supplies nutrients, controls temperature, filters waste, and maintains fluid balance. Meanwhile, the neurons are firing and interpreting signals, adapting from each interaction.

The CL1's compact energy and hardware footprint could make it attractive for extended experiments. A rack of CL1 units consumes 850-1,000 watts, notably lower than the tens of kilowatts required by a data center setup running AI workloads. "Brain cells generate small electrical pulses to communicate to a broader network," says Cortical Labs Chief Scientific Officer Brett Kagan. "We can do something similar by inputting small electrical pulses representing bits of information, and then reading their responses. The CL1 does this in real time using simple code abstracted through multiple interacting layers of firmware and hardware. Sub-millisecond loops read information, act on it, and write new information into the cell culture." The company sees CL1 as foundational for testing neuropsychiatric treatments, leveraging living cells to explore genetic and functional differences. "It allows people to study the effects of stimulation, drugs and synthetic lesions on how neuronal circuits learn and respond in a closed-loop setup, when the neuronal network is in reciprocal exchange with some simulated world," says theoretical neuroscientist Karl Friston of University College London. "In short, experimentalists now have at hand a little 'brain in a vat,' something philosophers have been dreaming about for decades."

There was excitement when biotech company Collosal announced genetically modified grey wolves (first hailed as a "de-extinction" of the Dire wolf species after several millennia). "But bioethicists and conservationists are expressing unease with the kind of scientific research," writes the Chicago Tribune. [Alternate URL here.] "Unfortunately, as clever as this science is ... it's can-do science and not should-do science," said Lindsay Marshall, director of science in animal research at Humane World for Animals, formerly the Humane Society of the U.S.... Ed Heist, a professor at Southern Illinois University and a conservation geneticist, said the news bothered him. "This is not conservation, but people conflate it," he said. "The point is entertainment...."

Naomi Louchouarn [program director of wildlife partnerships at Humane World for Animals], has dedicated her studies and research to the relationship between humans and animals, specifically carnivores like gray wolves. "The reason our current endangered species are becoming extinct is because we don't know how to coexist with them," she said. "And this doesn't solve that problem at all." Humans can treat the symptoms of wildlife conflict with "big, flashy silver bullets" and "in this case, advanced, inefficient science," she said, but the real solution is behavioral change. "Assuming that we could actually bring back a full population of animals," Louchouarn said, "which is so difficult and so crazy — that's a big if — I don't understand the point of trying to bring back a woolly mammoth when we already can't coexist with elephants."
The article notes that even Colossal's chief science officer says their technology is at best one of several tools for fighting biodiversity loss, calling it a battle which humans are 'not close to winning'... We as a global community need to continue to invest in traditional approaches to conservation and habitat preservation, as well as in the protection of living endangered species."

But the article adds that the Trump administration "is citing the case of the dire wolf as it moves to reduce federal protections under the Endangered Species Act of 1973." (Wednesday U.S. interior secretary Doug Burgum has even posted on X "The concept of 'de-extinction' can serve as a bedrock for modern species conservation.")

And the article adds that "During a livestreamed town hall with Interior Department employees on April 9, Burgum said: "If we're going to be in anguish about losing a species, now we have an opportunity to bring them back. Pick your favorite species and call up Colossal. Ken Angielczyk, curator of mammal fossils at the Field Museum who researches extinct species that lived 200 to 300 million years ago, said it's a misguided approach. "If that's the basis ... for changing regulations related to the endangered species list, that is very, very premature," he said. "Because we can't resurrect things.... If the purpose is to restore the damage to the shared ecosystem, we have that opportunity right now," she said. "And that's the necessity immediately...."

"This whole idea that extinction is reversible is so dangerous," Marshall said, "because then it stops us caring."
Thanks to long-time Slashdot reader walterbyrd for sharing the news.

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. WSJ: Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., while barring companies from working with Chinese biotech suppliers, the National Security Commission on Emerging Biotechnology said in a report Tuesday. To achieve its goals, the federal government and U.S.-based researchers will also need to work with allies and partners around the world.

"China is quickly ascending to biotechnology dominance, having made biotechnology a strategic priority for 20 years," the commission said. Without prompt action, the U.S. risks "falling behind, a setback from which we may never recover." The findings convey the depth of worry in Washington that China's rapid biotechnology advances jeopardize U.S. national security. Yet translating the concern into tangible actions could prove challenging.

[...] China plays a large role supplying drug ingredients and even some generic medicines to the U.S. For years, it produced copycat versions of drugs developed in the West. Recent years have seen it become a formidable hub of biotechnology innovation, after the Chinese government gave priority to the field as a critical sector in China's efforts to become a scientific superpower.

An anonymous reader quotes a report from 404 Media: The creator of an open source genetic database is shutting it down and deleting all of its data because he has come to believe that its existence is dangerous with "a rise in far-right and other authoritarian governments" in the United States and elsewhere. "The largest use case for DTC genetic data was not biomedical research or research in big pharma," Bastian Greshake Tzovaras, the founder of OpenSNP, wrote in a blog post. "Instead, the transformative impact of the data came to fruition among law enforcement agencies, who have put the genealogical properties of genetic data to use."

OpenSNP has collected roughly 7,500 genomes over the last 14 years, primarily by allowing people to voluntarily submit their own genetic information they have downloaded from 23andMe. With the bankruptcy of 23andMe, increased interest in genetic data by law enforcement, and the return of Donald Trump and rise of authoritarian governments worldwide, Greshake Tzovaras told 404 Media he no longer believes it is ethical to run the database. "I've been thinking about it since 23andMe was on the verge of bankruptcy and been really considering it since the U.S. election. It definitely is really bad over there [in the United States]," Greshake Tzovaras told 404 Media. "I am quite relieved to have made the decision and come to a conclusion. It's been weighing on my mind for a long time."

Greshake Tzovaras said that he is proud of the OpenSNP project, but that, in a world where scientific data is being censored and deleted and where the Trump administration has focused on criminalizing immigrants and trans people, he now believes that the most responsible thing to do is to delete the data and shut down the project. "Most people in OpenSNP may not be at particular risk right now, but there are people from vulnerable populations in here as well," Greshake Tzovaras said. "Thinking about gender representation, minorities, sexual orientation -- 23andMe has been working on the whole 'gay gene' thing, it's conceivable that this would at some point in the future become an issue." "Across the globe there is a rise in far-right and other authoritarian governments. While they are cracking down on free and open societies, they are also dedicated to replacing scientific thought and reasoning with pseudoscience across disciplines," Greshake Tzovaras wrote. "The risk/benefit calculus of providing free & open access to individual genetic data in 2025 is very different compared to 14 years ago. And so, sunsetting openSNP -- along with deleting the data stored within it -- feels like it is the most responsible act of stewardship for these data today."

"The interesting thing to me is there are data preservation efforts in the U.S. because the government is deleting scientific data that they don't like. This is approaching that same problem from a different direction," he added. "We need to protect the people in this database. I am supportive of preserving scientific data and knowledge, but the data comes second -- the people come first. We prefer deleting the data."

An anonymous reader shared this report from the Mercury News: After a year of fastidious planning, a microscopic sample of the ultra-rare radioactive element berkelium arrived at a Berkeley Lab. With just 48 hours to experiment before it would become unusable, a group of nearly 20 researchers focused intently on creating a brand-new molecule. Using a chemical glove box, a polycarbonate glass box with protruding gloves that shields substances from oxygen and moisture, scientists combined the berkelium metal with an organic molecule containing only carbon and hydrogen to create a chemical reaction... [Post-doc researcher Dominic] Russo, researcher Stefan Minasian, and 17 other scientists at Lawrence Berkeley National Laboratory had created berkelocene, a new molecule that usurps theorists' expectations about how carbon bonds with heavy-metal elements.

In the future, berkelocene may help humanity safely dispose of nuclear waste, according to a study published in the academic journal Science... The new molecular structure is, in the nomenclature of researchers, a "sandwich." In this formation, a berkelium atom, serving as the filling, lays in between two 8-membered carbon rings — the "bread" — and resembles an atomic foot-long sub. "It has this very symmetric geometry, and it's the first time that that's been observed," Minasian said.
The researchers believe more accurate models for how actinide elements like uranium behave will help solve problems related to long-term nuclear waste storage.

In an op-ed for MIT Technology Review, authors Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi make the case for human "bodyoids" that could reduce animal testing, improve drug development, and alleviate organ shortages: Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation so long? These challenges stem in large part from a common root cause: a severe shortage of ethically sourced human bodies. It may be disturbing to characterize human bodies in such commodifying terms, but the unavoidable reality is that human biological materials are an essential commodity in medicine, and persistent shortages of these materials create a major bottleneck to progress.

This imbalance between supply and demand is the underlying cause of the organ shortage crisis, with more than 100,000 patients currently waiting for a solid organ transplant in the US alone. It also forces us to rely heavily on animals in medical research, a practice that can't replicate major aspects of human physiology and makes it necessary to inflict harm on sentient creatures. In addition, the safety and efficacy of any experimental drug must still be confirmed in clinical trials on living human bodies. These costly trials risk harm to patients, can take a decade or longer to complete, and make it through to approval less than 15% of the time.

There might be a way to get out of this moral and scientific deadlock. Recent advances in biotechnology now provide a pathway to producing living human bodies without the neural components that allow us to think, be aware, or feel pain. Many will find this possibility disturbing, but if researchers and policymakers can find a way to pull these technologies together, we may one day be able to create "spare" bodies, both human and nonhuman. These could revolutionize medical research and drug development, greatly reducing the need for animal testing, rescuing many people from organ transplant lists, and allowing us to produce more effective drugs and treatments. All without crossing most people's ethical lines.

Although it may seem like science fiction, recent technological progress has pushed this concept into the realm of plausibility. Pluripotent stem cells, one of the earliest cell types to form during development, can give rise to every type of cell in the adult body. Recently, researchers have used these stem cells to create structures that seem to mimic the early development of actual human embryos. At the same time, artificial uterus technology is rapidly advancing, and other pathways may be opening to allow for the development of fetuses outside of the body. Such technologies, together with established genetic techniques to inhibit brain development, make it possible to envision the creation of "bodyoids" -- a potentially unlimited source of human bodies, developed entirely outside of a human body from stem cells, that lack sentience or the ability to feel pain.

An anonymous reader quotes a report from 404 Media: 23andMe filed for Chapter 11 bankruptcy Sunday, leaving the fate of millions of people's genetic information up in the air as the company deals with the legal and financial fallout of not properly protecting that genetic information in the first place. The filing shows how dangerous it is to provide your DNA directly to a large, for-profit commercial genetic database; 23andMe is now looking for a buyer to pull it out of bankruptcy. 23andMe said in court documents viewed by 404 Media that since hackers obtained personal data about seven million of its customers in October 2023, including, in some cases "health-related information based upon the user's genetics," it has faced "over 50 class action and state court lawsuits," and that "approximately 35,000 claimants have initiated, filed, or threatened to commence arbitration claims against the company." It is seeking bankruptcy protection in part to simplify the fallout of these legal cases, and because it believes it may not have money to pay for the potential damages associated with these cases.

CEO and cofounder Anne Wojcicki announced she is leaving the company as part of this process. The company has the genetic data of more than 15 million customers. According to its Chapter 11 filing, 23andMe owes money to a host of pharmaceutical companies, pharmacies, artificial intelligence companies (including a company called Aganitha AI and Coreweave), as well as health insurance companies and marketing companies. Shortly before the filing, California Attorney General Rob Bonta issued an "urgent" alert to 23andMe customers: "Given 23andMe's reported financial distress, I remind Californians to consider invoking their rights and directing 23andMe to delete their data and destroy any samples of genetic material held by the company."

In a letter to customers Sunday, 23andMe said: "Your data remains protected. The Chapter 11 filing does not change how we store, manage, or protect customer data. Our users' privacy and data are important considerations in any transaction, and we remain committed to our users' privacy and to being transparent with our customers about how their data is managed." It added that any buyer will have to "comply with applicable law with respect to the treatment of customer data."

404 Media's Jason Koebler notes that "there's no way of knowing who is going to buy it, why they will be interested, and what will become of its millions of customers' DNA sequences. 23andMe has claimed over the years that it strongly resists law enforcement requests for information and that it takes customer security seriously. But the company has in recent years changed its terms of service, partnered with big pharmaceutical companies, and, of course, was hacked."

An anonymous reader quotes a report from Ars Technica: [A] team of Korean researchers [describe] how they've engineered a bacterial strain that can make a useful polymer starting with nothing but glucose as fuel. The system they developed is based on an enzyme that the bacteria use when they're facing unusual nutritional conditions, and it can be tweaked to make a wide range of polymers. The researchers focused on the system bacterial cells use for producing polyhydroxyalkanoates (PHAs). These chemicals are formed when the bacterial cells continue to have a good supply of carbon sources and energy, but they lack some other key nutrients needed to grow and divide. Under these circumstances, the cell will link together small molecules that contain a handful of carbons, forming a much larger polymer. When nutritional conditions improve, the cell can simply break down the polymer and use the individual molecules it contained.

The striking thing about this system is that it's not especially picky about the identity of the molecules it links into the polymer. So far, over 150 different small molecules have been found incorporated into PHAs. It appears that the enzyme that makes the polymer, PHA synthase, only cares about two things: whether the molecule can form an ester bond (PHAs are polyesters), and whether it can be linked to a molecule that's commonly used as an intermediate in the cell's biochemistry, Coenzyme A. Normally, PHA synthase forms links between molecules that run through an oxygen atom. But it's also possible to form a related chemical link that instead runs through a nitrogen atom, like those found on amino acids. There were no known enzymes, however, that catalyze these reactions. So, the researchers decided to test whether any existing enzymes could be induced to do something they don't normally do. [...]

Overall, the system they develop is remarkably flexible, able to incorporate a huge range of chemicals into a polymer. This should allow them to tune the resulting plastic across a wide range of properties. And, considering the bonds were formed via enzyme, the resulting polymer will almost certainly be biodegradable. There are, however, some negatives. The process doesn't allow complete control over what gets incorporated into the polymer. You can bias it toward a specific mix of amino acids or other chemicals, but you can't entirely stop the enzyme from incorporating random chemicals from the cell's metabolism into the polymer at some level. There's also the issue of purifying the polymer from all the rest of the cell components before incorporating it into manufacturing. Production is also relatively slow compared to large-scale industrial production. The findings have been published in the journal Nature Chemical Biology.

Damaged corneas were repaired at a Harvard teaching hospital in a unique clinical trial, reports New Atlas: Since it's on the frontline of potential hazards from the outside world, the cornea features a population of limbal epithelial stem cells, which repair minor damage to keep the surface smooth and functional... The new study, conducted by scientists at Massachusetts Eye and Ear, investigated a new treatment called cultivated autologous limbal epithelial cells (CALEC). This involves removing stem cells from a patient's uninjured eye, growing their population in the lab for a few weeks, then surgically transplanting them into the injured eye.

The phase 1/2 trial recruited 14 patients to undergo the procedure, and followed them for 18 months afterwards... By the first checkup at three months, the corneas of seven (50%) of the participants had been completely restored. By the 12-month mark, that number had increased to 11 (79%) patients. Two other participants met the definition for partial success, so the team claims an overall success rate of 92% for CALEC.

An anonymous reader quotes a report from The Guardian: Many of us have been guilty of binning a mushy, overripe banana -- but now scientists say they have a solution with the launch of a genetically engineered non-browning banana. The product is the latest in a series of gene-edited fruits and vegetables designed to have a longer shelf life. Scientists say the technology is emerging as a powerful new weapon against food waste, which occurs globally on an epic scale. The banana, developed by Tropic, a biotech company based in Norwich, is said to remain fresh and yellow for 12 hours after being peeled and is less susceptible to turning brown when bumped during harvesting and transportation.

The company has also developed a slow-ripening banana that has been approved in several countries, which it plans to launch later in the year. Other research teams are working on lettuce that wilts more slowly, bruise-resistant apples and potatoes and identifying the genes that determine how quickly grapes and blueberries shrivel. [...] The company worked out how to disable a gene responsible for the production of an enzyme called polyphenol oxidase, which causes browning. The same gene is silenced in Arctic apples, a genetically modified variety, which has been sold in the US since 2017, and blocking the production of polyphenol oxidase has been shown to work in tomatoes, melon, kiwifruits and mushrooms. In the bananas, Tropic made precise changes to existing genes without introducing foreign genetic material. The report notes that an estimated 33% of the produce that is harvested worldwide is never consumed due to the short shelf-life of many fruit and vegetable products. Bananas are among the most thrown-away foods, with some 5 billion bananas tossed in the U.S. each year.

Britain, the birthplace of the Industrial Revolution, now suffers from its opposite: profound energy shortages and deep affordability crises [non-paywalled link]. A new report titled "Foundations" identifies the root cause -- "it is difficult to build almost anything, anywhere" in the UK.

Housing exemplifies this malaise. Since the 1990s, homeownership among young British workers has halved while housing prices doubled. The 1947 Town and Country Planning Act effectively nationalized development rights, requiring special permission for new construction and establishing restrictive "green belts." Despite Margaret Thatcher's market reforms, British house-building never recovered.

This constrictive policy has stymied potential growth beyond housing, Atlantic reports. Cambridge remains a small city despite biotech breakthroughs that might have transformed it into a major hub. Transit infrastructure languishes -- Leeds is Europe's largest city without a metro system. Energy production has collapsed, with per capita electricity generation now roughly one-third of America's.

Britain faces a self-imposed scarcity crisis. Environmental regulations, while beneficial, created a one-way system where lawsuits easily block development. As co-author Sam Bowman summarized: "Europe has an energy problem; the Anglosphere has a housing problem; Britain has both." The solution requires comprehensive reform-- overhauling the planning system, reducing anti-growth litigation, and encouraging energy production to unlock what the private sector "already wants to do."

San Francisco-based biotech startup Loyal says a drug it developed to increase dogs' lifespan "has passed a significant milestone on the way to regulatory approval," reports the Washington Post: The Food and Drug Administration certified the daily pill as having a "reasonable expectation of effectiveness" at extending senior dogs' lifespans. The regulator's Center for Veterinary Medicine still has to certify that the drug is safe and that Loyal can manufacture it at scale before vets can prescribe the pill to dogs 10 years or older that weigh 14 pounds or more. Loyal's CEO, Celine Halioua, estimates that the process should be complete by the end of 2025 and called the FDA's initial recognition "a key step" to extending dogs' lives...

In the past decade, a subculture of tech entrepreneurship has focused on helping people stave off death, hawking custom-made dietary supplements and $2,500 full-body MRIs and investing in the development of antiaging drugs, among many other efforts. According to data firm Pitchbook, about $900 million in venture capital has been poured into antiaging and longevity start-ups in the past 12 months. Loyal has raised more than $150 million in venture funding since its 2019 founding to develop lifespan-extending drugs initially focused on canines.

Launching veterinary drugs is in some ways easier than winning approval for human treatments. Because dogs and humans have evolved alongside one another, Halioua hopes to eventually apply her findings about pets to help prolong their owners' lives. "If we can successfully delay the onset and severity of age-related diseases in dogs, it's extremely compelling evidence that it will also do that in humans," Halioua said. The biological processes of aging unfold faster in dogs because they live such short lives, she said, helping researchers and entrepreneurs probe how they work.
"Loyal's pill is a result of research into how to mimic the life-extending benefit of caloric restriction without the appetite suppression," according to the article, "and without the need for an owner to restrict their dog's food.

"The drug aims to improve a dog's metabolic fitness, or the body's ability to convert nutrients into energy and regulate hormones, which declines in humans and canines with age..."

"Elizabeth Holmes' fraud conviction has been upheld by a federal appellate panel," writes Slashdot reader ClickOnThis. MSNBC reports: A three-judge panel of the 9th U.S. Circuit Court of Appeals on Monday affirmed the convictions, sentences and nine-figure restitution ordered against both Holmes and Theranos president, Ramesh "Sunny" Balwani. [...] Theranos was supposedly going to revolutionize medical laboratory testing with the ability to run fast, accurate and affordable tests with just a drop of blood from a finger prick. "But the vision sold by Holmes and Balwani was nothing more than a mirage," 9th Circuit Judge Jacqueline H. Nguyen wrote (PDF) for the panel, adding that the "grandiose achievements touted by Holmes and Balwani were half-truths and outright lies."

Holmes was convicted of crimes related to fraud against investors while the jury acquitted her or hung on other counts. Balwani was convicted on all counts at his trial. The federal panel rejected a slew of arguments from both defendants, including that their trials featured improper testimony from Theranos employees. While the ruling is a major setback for the defendants, they can further appeal to a fuller panel of 9th Circuit judges and the Supreme Court, which generally has broad discretion over whether to accept cases for review.

Leveraging AI tools like RFDiffusion and PLACER, researchers were able to design a novel enzyme capable of breaking down plastic by targeting ester bonds, a key component in polyester. Ars Technica reports: The researchers started out by using the standard tools they developed to handle protein design, including an AI tool named RFDiffusion, which uses a random seed to generate a variety of protein backgrounds. In this case, the researchers asked RFDiffusion to match the average positions of the amino acids in a family of ester-breaking enzymes. The results were fed to another neural network, which chose the amino acids such that they'd form a pocket that would hold an ester that breaks down into a fluorescent molecule so they could follow the enzyme's activity using its glow.

Of the 129 proteins designed by this software, only two of them resulted in any fluorescence. So the team decided they needed yet another AI. Called PLACER, the software was trained by taking all the known structures of proteins latched on to small molecules and randomizing some of their structure, forcing the AI to learn how to shift things back into a functional state (making it a generative AI). The hope was that PLACER would be trained to capture some of the structural details that allow enzymes to adopt more than one specific configuration over the course of the reaction they were catalyzing. And it worked. Repeating the same process with an added PLACER screening step boosted the number of enzymes with catalytic activity by over three-fold.

Unfortunately, all of these enzymes stalled after a single reaction. It turns out they were much better at cleaving the ester, but they left one part of it chemically bonded to the enzyme. In other words, the enzymes acted like part of the reaction, not a catalyst. So the researchers started using PLACER to screen for structures that could adopt a key intermediate state of the reaction. This produced a much higher rate of reactive enzymes (18 percent of them cleaved the ester bond), and two -- named "super" and "win" -- could actually cycle through multiple rounds of reactions. The team had finally made an enzyme.

By adding additional rounds alternating between structure suggestions using RFDiffusion and screening using PLACER, the team saw the frequency of functional enzymes increase and eventually designed one that had an activity similar to some produced by actual living things. They also showed they could use the same process to design an esterase capable of digesting the bonds in PET, a common plastic. The research has been published in the journal Science.

China issued guidelines on Friday to promote biotech cultivation, focusing on gene-editing tools and developing new wheat, corn, and soybean varieties, as part of efforts to ensure food security and boost agriculture technology. From a report: The 2024-2028 plan aims to achieve "independent and controllable" seed sources for key crops, with a focus to cultivate high-yield, multi-resistant wheat, corn and high-oil, high-yield soybean and rapeseed varieties. The move comes as China intensifies efforts to boost domestic yields of key crops like soybeans to reduce reliance on imports from countries such as the United States amid a looming trade war.

An anonymous reader quotes a report from The Guardian: A groundbreaking NHS trial will attempt to boost patients' mood using a brain-computer-interface that directly alters brain activity using ultrasound. The device, which is designed to be implanted beneath the skull but outside the brain, maps activity and delivers targeted pulses of ultrasound to "switch on" clusters of neurons. Its safety and tolerability will be tested on about 30 patient in the 6.5 million-pound trial, funded by the UK's Advanced Research and Invention Agency (Aria).

[...] The latest trial will test a device developed by the US-based non-profit Forest Neurotech. In contrast to invasive implants, in which electrodes are inserted into a specific location in the brain, Forest 1 uses ultrasound to read-out and modify activity. Aria describes the device as "the most advanced BCI in the world" due to its ability to modify activity across multiple regions simultaneously. This widens potential future applications to a huge patient population affected by conditions such as depression, anxiety and epilepsy, which are all "circuit level" conditions rather than being localized in a specific brain region.

The NHS trial will recruit patients who, due to brain injury, have had part of their skull temporarily removed to relieve a critical buildup of pressure in the brain. This means the device can be tested without having to perform surgery. When placed beneath the skull, or in individuals with a skull defect, ultrasound can detect tiny changes in blood flow to produce 3D maps of brain activity with a spatial resolution of about 100 times that of a typical fMRI scan. The same implant can deliver focused ultrasound to mechanically nudge neurons towards firing, providing a way to remotely dial activity up at precise locations. Participants will wear the device on their scalp at the site of the skull defect for two hours. Their brain activity will be measured and researchers will test whether patients' mood and feelings of motivation can be reliably altered.

There are safety considerations, as ultrasound can cause tissue to heat up. Prof Elsa Fouragnan, a neuroscientist at the University of Plymouth, which is collaborating on the project, said: "What we're trying to minimize is heat. There's a safety and efficacy trade-off." She added that it would also be important to ensure that personality or decision-making were not altered in unintended ways -- for instance, making someone more impulsive. The study will run for three and a half years starting from March, with the first eight months focused on securing regulatory approval. If successful, Forest hopes to move into a full clinical trial for a condition such as depression. Aimun Jamjoom, a consultant neurosurgeon at the Barking, Havering and Redbridge university hospitals NHS trust, who is leading the project, said: "[T]he ability to offer a safer form of surgery is very exciting. If you look at conditions like depression or epilepsy, [up to] a third of these patients just don't get better. It's those groups where a technology like this could be a life-changing solution."

Convicted Theranos founder, Elizabeth Holmes, had her first interview since being reported to prison in 2023, telling People magazine that she is still working on "research and inventions" in the healthcare space. Here's an excerpt from the article: Scheduled for release on April 3, 2032, Holmes says she hopes to travel with her family and to fight for reform of criminal justice system. She recently drafted an American Freedom Act bill -- a seven-page handwritten document -- to bolster the presumption of innocence and change criminal procedure. "This will be my life's work," says Holmes, adding that she is speaking out now as part of her mission to advocate on behalf of incarcerated persons and those ripped away from their children.

And, despite her global reputation as a biotech con artist who put lives at risk, she says she's continuing to write patents for new inventions and plans to resume her career in healthcare technology after her release. "There is not a day I have not continued to work on my research and inventions," she says. "I remain completely committed to my dream of making affordable healthcare solutions available to everyone."

For now, however, she is sustained by weekend visits from her family, when she can cuddle Invicta, watch William gather acorns in the prison yard and hold Evans's hand and briefly hug and kiss. (Conjugal visits are not allowed.) "It kills me to put my family through pain the way I do," she says. "But when I look back on my life, and these angels that have come into it, I can get through anything. It makes me want to fight for all of it."

An anonymous reader quotes a report from The Guardian: Bolstered by Silicon Valley investment, scientists are making such rapid progress that lab-grown human eggs and sperm could be a reality within a decade, a meeting of the Human Fertilization and Embryology Authority board heard last week (PDF). In-vitro gametes (IVGs), eggs or sperm that are created in the lab from genetically reprogrammed skin or stem cells, are viewed as the holy grail of fertility research. The technology promises to remove age barriers to conception and could pave the way for same-sex couples to have biological children together. It also poses unprecedented medical and ethical risks, which the HFEA now believes need to be considered in a proposed overhaul of fertility laws.

Peter Thompson, chief executive of the HFEA, said: "In-vitro gametes have the potential to vastly increase the availability of human sperm and eggs for research and, if proved safe, effective, and publicly acceptable, to provide new fertility treatment options for men with low sperm counts and women with low ovarian reserve." The technology also heralds more radical possibilities including "solo parenting" and "multiplex parenting." Julia Chain, chair of HFEA, said: "It feels like we ought to have Steven Spielberg on this committee," in a brief moment of levity in the discussion of how technology should be regulated. Lab-grown eggs have already been used produce healthy babies in mice -- including ones with two biological fathers. The equivalent feat is yet to be achieved using human cells, but US startups such as Conception and Gameto claim to be closing in on this prize.

The HFEA meeting noted that estimated timeframes ranged from two to three years -- deemed to be optimistic -- to a decade, with several clinicians at the meeting sharing the view that IVGs appeared destined to become "a routine part of clinical practice." The clinical use of IVGs would be prohibited under current law and there would be significant hurdles to proving that IVGs are safe, given that any unintended genetic changes to the cells would be passed down to all future generations. The technology also opens up myriad ethical issues. Thompson said: "Research on IVGs is progressing quickly but it is not yet clear when they might be a viable option in treatment. IVGs raise important questions and that is why the HFEA has recommended that they should be subject to statutory regulation in time, and that biologically dangerous use of IVGs in treatment should never be permitted."

"This is the latest of a range of detailed recommendations on scientific developments that we are looking at to future-proof the HFE Act, but any decisions around UK modernizing fertility law are a matter for parliament."

OpenAI has developed a language model designed for engineering proteins, capable of converting regular cells into stem cells. It marks the company's first venture into biological data and demonstrates AI's potential for unexpected scientific discoveries. An anonymous reader quotes a report from MIT Technology Review: Last week, OpenAI CEO Sam Altman said he was "confident" his company knows how to build an AGI, adding that "superintelligent tools could massively accelerate scientific discovery and innovation well beyond what we are capable of doing on our own." The protein engineering project started a year ago when Retro Biosciences, a longevity research company based in San Francisco, approached OpenAI about working together. That link-up did not happen by chance. Sam Altman, the CEO of OpenAI, personally funded Retro with $180 million, as MIT Technology Review first reported in 2023. Retro has the goal of extending the normal human lifespan by 10 years. For that, it studies what are called Yamanaka factors. Those are a set of proteins that, when added to a human skin cell, will cause it to morph into a young-seeming stem cell, a type that can produce any other tissue in the body. [...]

OpenAI's new model, called GPT-4b micro, was trained to suggest ways to re-engineer the protein factors to increase their function. According to OpenAI, researchers used the model's suggestions to change two of the Yamanaka factors to be more than 50 times as effective -- at least according to some preliminary measures. [...] The model does not work the same way as Google's AlphaFold, which predicts what shape proteins will take. Since the Yamanaka factors are unusually floppy and unstructured proteins, OpenAI said, they called for a different approach, which its large language models were suited to. The model was trained on examples of protein sequences from many species, as well as information on which proteins tend to interact with one another. While that's a lot of data, it's just a fraction of what OpenAI's flagship chatbots were trained on, making GPT-4b an example of a "small language model" that works with a focused data set.

Once Retro scientists were given the model, they tried to steer it to suggest possible redesigns of the Yamanaka proteins. The prompting tactic used is similar to the "few-shot" method, in which a user queries a chatbot by providing a series of examples with answers, followed by an example for the bot to respond to. Although genetic engineers have ways to direct evolution of molecules in the lab, they can usually test only so many possibilities. And even a protein of typical length can be changed in nearly infinite ways (since they're built from hundreds of amino acids, and each acid comes in 20 possible varieties). OpenAI's model, however, often spits out suggestions in which a third of the amino acids in the proteins were changed. "We threw this model into the lab immediately and we got real-world results," says Retro's CEO, Joe Betts-Lacroix. He says the model's ideas were unusually good, leading to improvements over the original Yamanaka factors in a substantial fraction of cases.

An anonymous reader quotes a report from VentureBeat: Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth. Dallas- and Boston-based Colossal is making strides in the scientific breakthroughs toward "de-extinction," or bringing back extinct species like the woolly mammoth, thylacine and the dodo. [...] Since launching in September 2021, Colossal has raised $435 million in total funding. This latest round of capital places the company at a $10.2 billion valuation. Colossal will leverage this latest infusion of capital to continue to advance its genetic engineering technologies while pioneering new revolutionary software, wetware and hardware solutions, which have applications beyond de-extinction including species preservation and human healthcare.

"Our recent successes in creating the technologies necessary for our end-to-end de-extinction toolkit have been met with enthusiasm by the investor community. TWG Global and our other partners have been bullish in their desire to help us scale as quickly and efficiently as possible," said CEO Colossal Ben Lamm, in a statement. "This funding will grow our team, support new technology development, expand our de-extinction species list, while continuing to allow us to carry forth our mission to make extinction a thing of the past." Here's a summary of the startup's progress on its efforts to bring back the woolly mammoth, thylacine and the dodo:

Woolly Mammoth De-extinction Progress
- Generated chromosome-scale reference genomes for elephants and the first de novo assembled mammoth genome
- Acquired and aligned 60+ ancient mammoth genomes and 30+ genomes of extant elephant species, improving mammoth-specific variant accuracy
- Derived pluripotent stem cells for Asian elephants, advancing reproductive technologies essential for de-extinction

Thylacine De-extinction Progress
- Created a 99.9% complete ancient genome for the thylacine using long-read and RNA sequencing
- Assembled telomere-to-telomere genomes of dasyurid species to understand evolutionary relationships and support conservation of marsupials
- Progress in genomics and reproductive technologies positions Colossal ahead of schedule on critical de-extinction steps

Dodo De-extinction Progress
- Completed high-coverage genomes for the dodo, its relatives, and the critically endangered manumea
- Developed tools for avian genome engineering, including techniques for craniofacial gene-editing and primordial germ cell cultivation
- Significant advances in avian-specific genetic techniques are driving progress toward dodo restoration and bird conservation